
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="4DDED33F88AEA1C312D33F00278EB25D.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="bmjgroup">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8685623/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Archives of Disease in Childhood">
<meta name="citation_title" content="Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis">
<meta name="citation_author" content="Rovina Ruslami">
<meta name="citation_author_institution" content="Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia">
<meta name="citation_author" content="Fajri Gafar">
<meta name="citation_author_institution" content="Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands">
<meta name="citation_author" content="Vycke Yunivita">
<meta name="citation_author_institution" content="Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia">
<meta name="citation_author" content="Ida Parwati">
<meta name="citation_author_institution" content="Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia">
<meta name="citation_author" content="Ahmad R Ganiem">
<meta name="citation_author_institution" content="Department of Neurology, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia">
<meta name="citation_author" content="Rob E Aarnoutse">
<meta name="citation_author_institution" content="Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands">
<meta name="citation_author" content="Bob Wilffert">
<meta name="citation_author_institution" content="Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands">
<meta name="citation_author_institution" content="Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands">
<meta name="citation_author" content="Jan-Willem C Alffenaar">
<meta name="citation_author_institution" content="School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia">
<meta name="citation_author_institution" content="Westmead Hospital, Sydney, New South Wales, Australia">
<meta name="citation_author" content="Heda M Nataprawira">
<meta name="citation_author_institution" content="Division of Pediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia">
<meta name="citation_publication_date" content="2021 Jun 28">
<meta name="citation_volume" content="107">
<meta name="citation_issue" content="1">
<meta name="citation_firstpage" content="70">
<meta name="citation_doi" content="10.1136/archdischild-2020-321426">
<meta name="citation_pmid" content="34183327">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8685623/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8685623/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8685623/pdf/archdischild-2020-321426.pdf">
<meta name="description" content="To assess the pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents with tuberculous meningitis (TBM). Prospective observational pharmacokinetic study with an exploratory ...">
<meta name="og:title" content="Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="To assess the pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents with tuberculous meningitis (TBM). Prospective observational pharmacokinetic study with an exploratory ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8685623/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="8685623">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1136/archdischild-2020-321426"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/archdischild-2020-321426.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC8685623%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/8685623/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/8685623/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC8685623/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-bmjgroup.png" alt="BMJ Open Access logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to BMJ Open Access" title="Link to BMJ Open Access" shape="default" href="https://doi.org/10.1136/archdischild-2020-321426" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Arch Dis Child</button></div>. 2021 Jun 28;107(1):70–77. doi: <a href="https://doi.org/10.1136/archdischild-2020-321426" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1136/archdischild-2020-321426</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Arch%20Dis%20Child%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Arch%20Dis%20Child%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Arch%20Dis%20Child%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Arch%20Dis%20Child%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ruslami%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Rovina Ruslami</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Rovina Ruslami</span></h3>
<div class="p">
<sup>1</sup>
Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ruslami%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Rovina Ruslami</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gafar%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Fajri Gafar</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Fajri Gafar</span></h3>
<div class="p">
<sup>2</sup>
Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gafar%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fajri Gafar</span></a>
</div>
</div>
<sup>2,</sup><sup>✉,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yunivita%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Vycke Yunivita</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Vycke Yunivita</span></h3>
<div class="p">
<sup>1</sup>
Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yunivita%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Vycke Yunivita</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Parwati%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Ida Parwati</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Ida Parwati</span></h3>
<div class="p">
<sup>3</sup>
Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Parwati%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Ida Parwati</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ganiem%20AR%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Ahmad R Ganiem</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Ahmad R Ganiem</span></h3>
<div class="p">
<sup>4</sup>
Department of Neurology, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ganiem%20AR%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahmad R Ganiem</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aarnoutse%20RE%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Rob E Aarnoutse</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Rob E Aarnoutse</span></h3>
<div class="p">
<sup>5</sup>
Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aarnoutse%20RE%22%5BAuthor%5D" class="usa-link"><span class="name western">Rob E Aarnoutse</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wilffert%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Bob Wilffert</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Bob Wilffert</span></h3>
<div class="p">
<sup>2</sup>
Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
</div>
<div class="p">
<sup>6</sup>
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wilffert%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Bob Wilffert</span></a>
</div>
</div>
<sup>2,</sup><sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alffenaar%20JWC%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Jan-Willem C Alffenaar</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Jan-Willem C Alffenaar</span></h3>
<div class="p">
<sup>7</sup>
School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
</div>
<div class="p">
<sup>8</sup>
Westmead Hospital, Sydney, New South Wales, Australia
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alffenaar%20JWC%22%5BAuthor%5D" class="usa-link"><span class="name western">Jan-Willem C Alffenaar</span></a>
</div>
</div>
<sup>7,</sup><sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nataprawira%20HM%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Heda M Nataprawira</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Heda M Nataprawira</span></h3>
<div class="p">
<sup>9</sup>
Division of Pediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia
</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nataprawira%20HM%22%5BAuthor%5D" class="usa-link"><span class="name western">Heda M Nataprawira</span></a>
</div>
</div>
<sup>9</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>
Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
</div>
<div id="aff2">
<sup>2</sup>
Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
</div>
<div id="aff3">
<sup>3</sup>
Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia
</div>
<div id="aff4">
<sup>4</sup>
Department of Neurology, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia
</div>
<div id="aff5">
<sup>5</sup>
Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
</div>
<div id="aff6">
<sup>6</sup>
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
</div>
<div id="aff7">
<sup>7</sup>
School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
</div>
<div id="aff8">
<sup>8</sup>
Westmead Hospital, Sydney, New South Wales, Australia
</div>
<div id="aff9">
<sup>9</sup>
Division of Pediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia
</div>
<div class="author-notes p">
<div class="fn" id="corresp1">
<sup>✉</sup><p class="display-inline">
Correspondence to Fajri Gafar, Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen 9713 AV, The Netherlands; <span>f.gafar@rug.nl</span>; <span>fajri.gafar@gmail.com</span>
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2020 Dec 14; Accepted 2021 Jun 14; Issue date 2022 Jan.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.</div>
<p>This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC8685623  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34183327/" class="usa-link">34183327</a>
</div>
<div class="ra xbox p" role="complementary" aria-label="Related or updated information about this article"><div>See "<a href="https://pubmed.ncbi.nlm.nih.gov/34911685/" class="usa-link">Improved treatment for children with tuberculous meningitis: acting on what we know.</a>" on page 68.</div></div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Objective</h3>
<p>To assess the pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents with tuberculous meningitis (TBM).</p></section><section id="sec2"><h3 class="pmc_sec_title">Design</h3>
<p>Prospective observational pharmacokinetic study with an exploratory pharmacokinetic/pharmacodynamic analysis.</p></section><section id="sec3"><h3 class="pmc_sec_title">Setting</h3>
<p>Hasan Sadikin Hospital, Bandung, Indonesia.</p></section><section id="sec4"><h3 class="pmc_sec_title">Patients</h3>
<p>Individuals aged 0–18 years clinically diagnosed with TBM and receiving first-line anti-tuberculosis drug dosages according to revised WHO-recommended treatment guidelines.</p></section><section id="sec5"><h3 class="pmc_sec_title">Interventions</h3>
<p>Plasma and cerebrospinal fluid (CSF) concentrations of isoniazid, rifampicin and pyrazinamide were assessed on days 2 and 10 of treatment.</p></section><section id="sec6"><h3 class="pmc_sec_title">Main outcome measures</h3>
<p>Plasma exposures during the daily dosing interval (AUC<sub>0–24</sub>), peak plasma concentrations (<em>C</em>
<sub>max</sub>) and CSF concentrations.</p></section><section id="sec7"><h3 class="pmc_sec_title">Results</h3>
<p>Among 20 eligible patients, geometric mean AUC<sub>0–24</sub> of isoniazid, rifampicin and pyrazinamide was 18.5, 66.9 and 315.5 hour∙mg/L on day 2; and 14.5, 71.8 and 328.4 hour∙mg/L on day 10, respectively. Large interindividual variabilities were observed in AUC<sub>0–24</sub> and <em>C</em>
<sub>max</sub> of all drugs. All patients had suboptimal rifampicin AUC<sub>0–24</sub> for TBM treatment indication and very low rifampicin CSF concentrations. Four patients developed grade 2–3 drug-induced liver injury (DILI) within the first 4 weeks of treatment, in whom anti-tuberculosis drugs were temporarily stopped, and no DILI recurred after reintroduction of rifampicin and isoniazid. AUC<sub>0–24</sub> of isoniazid, rifampicin and pyrazinamide along with <em>C</em>
<sub>max</sub> of isoniazid and pyrazinamide on day 10 were higher in patients who developed DILI than those without DILI (p&lt;0.05).</p></section><section id="sec8"><h3 class="pmc_sec_title">Conclusion</h3>
<p>Higher rifampicin doses are strongly warranted in treatment of children and adolescents with TBM. The association between higher plasma concentrations of isoniazid, rifampicin and pyrazinamide and the development of DILI needs confirmatory studies.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> pharmacology, therapeutics, microbiology</p></section></section><section class="abstract" id="abstract2"><hr class="headless">
<p>Children with TB meningitis do poorly, and this paper examines the pharmacokinetics of a commonly used drug combination to understand if drug factors contribute.</p></section><hr class="headless">
<section class="bt xbox font-sm" id="BX1"><h2 class="obj_head">What is already known on this topic?</h2>
<ul class="list" style="list-style-type:disc">
<li><p>Pharmacokinetic data of anti-tuberculosis (TB) drugs in children with tuberculous meningitis (TBM), particularly among the Indonesian paediatric population are lacking.</p></li>
<li><p>Suboptimal or toxic concentrations of anti-TB drugs contribute to unfavourable treatment outcomes.</p></li>
</ul></section><section class="bt xbox font-sm" id="BX2"><h2 class="obj_head">What this study adds?</h2>
<ul class="list" style="list-style-type:disc">
<li><p>Suboptimal plasma exposures and very low cerebrospinal fluid concentrations of rifampicin were observed in all patients; higher doses for this pivotal drug are strongly warranted.</p></li>
<li><p>The association between higher plasma concentrations of isoniazid, rifampicin and pyrazinamide and the development of drug-induced liver injury during TBM treatment needs confirmatory studies.</p></li>
</ul></section><section id="s1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Tuberculosis (TB) remains a major global health challenge with 1.2 million new paediatric cases and &gt;220 000 deaths in children aged &lt;15 years.<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1</sup></a> Tuberculous meningitis (TBM), as the most devastating manifestation of TB, accounts for approximately 20% of childhood TB mortality and results in neurological sequelae in more than 50% of survivors.<a href="#R2" class="usa-link" aria-describedby="R2"><sup>2 3</sup></a> Management of TBM poses continuing challenges, mainly due to the lack of understanding of the pathogenesis, a lengthy process in obtaining a definite diagnosis and suboptimal antimicrobial drug therapy.<a href="#R3" class="usa-link" aria-describedby="R3"><sup>3</sup></a> Delayed or late presentation of TBM is a major problem associated with worse outcomes.<a href="#R2" class="usa-link" aria-describedby="R2"><sup>2</sup></a>
</p>
<p>First-line anti-TB drug doses for treatment of children with TBM were revised by the WHO in 2010<a href="#R4" class="usa-link" aria-describedby="R4"><sup>4</sup></a> and are similar to those described for children with pulmonary TB (PTB).<a href="#R4" class="usa-link" aria-describedby="R4"><sup>4 5</sup></a> Following this revised dosing, sufficient plasma concentrations of isoniazid, rifampicin and pyrazinamide in children aged &lt;2 years were reported.<a href="#R6" class="usa-link" aria-describedby="R6"><sup>6</sup></a> However, subtherapeutic concentrations are still shown in high proportions of patients, particularly among young children for rifampicin and pyrazinamide<a href="#R7" class="usa-link" aria-describedby="R7"><sup>7–9</sup></a> and among fast acetylators for isoniazid.<a href="#R8" class="usa-link" aria-describedby="R8"><sup>8</sup></a> Furthermore, rifampicin and ethambutol have poor cerebrospinal fluid (CSF) penetration,<a href="#R10" class="usa-link" aria-describedby="R10"><sup>10 11</sup></a> which in case of TBM might lead to subtherapeutic concentrations at the site of infection. As an alternative TBM treatment option in children, the WHO suggests high-dose short-course therapy using isoniazid, rifampicin and pyrazinamide, with addition of ethionamide instead of ethambutol.<a href="#R5" class="usa-link" aria-describedby="R5"><sup>5 10 12</sup></a>
</p>
<p>Pharmacokinetic (PK) data of anti-TB drugs in children with TBM are lacking. PK evaluation of first-line anti-TB drugs is important because suboptimal concentrations might lead to unfavourable outcomes such as treatment failure and death.<a href="#R13" class="usa-link" aria-describedby="R13"><sup>13</sup></a> On the contrary, exposure to supratherapeutic concentrations might play a role in increasing the risk of adverse effects, like anti-TB drug-induced liver injury (DILI).<a href="#R14" class="usa-link" aria-describedby="R14"><sup>14</sup></a> We aimed to describe PK and safety/tolerability of isoniazid, rifampicin and pyrazinamide in Indonesian children and adolescents treated for TBM.</p></section><section id="s2"><h2 class="pmc_sec_title">Methods</h2>
<section id="s2-1"><h3 class="pmc_sec_title">Study design and population</h3>
<p>We performed a prospective observational PK and safety/tolerability study with an exploratory pharmacokinetic/pharmacodynamic (PK/PD) analysis in children and adolescents aged ≤18 years at Hasan Sadikin Hospital, Bandung, Indonesia, from March 2018 to January 2020. Written informed consent for study participation was obtained from parents/legal guardians, with additional verbal consent/assent from competent children aged &gt;12 years.</p>
<p>Initial screening among those with suspected meningitis included physical and clinical examinations, blood chemistry and haematology measurements, chest radiography and CSF analysis. Neuroradiology and microbiological examination from CSF/extraneural samples including smear microscopy for acid-fast bacilli, culture for <em>Mycobacterium tuberculosis</em> and GeneXpert MTB/RIF assay were performed, if applicable. In our setting, neuroradiology and GeneXpert testing during screening are not covered by government health insurance. Patients with definite TBM (microbiologically proven from CSF examination), and those clinically diagnosed with probable/possible TBM as determined by case definition criteria,<a href="#R15" class="usa-link" aria-describedby="R15"><sup>15</sup></a> were eligible for inclusion in this study. Our exclusion criteria were mixed bacterial meningitis, taking anti-TB drugs ≥3 days, HIV co-infection, baseline alanine/aspartate aminotransferases (ALT/AST) &gt;3× the ULN (reference ranges for ALT: 16–63 U/L and AST: 15–37 U/L) and medical conditions not allowing for inclusion according to the attending physician (eg, ventriculoperitoneal shunt, rapid clinical deterioration, kidney disease or autoimmune disorders).</p></section><section id="s2-2"><h3 class="pmc_sec_title">Treatment</h3>
<p>Treatment regimens were based on the current WHO guidelines in accordance with the Indonesian Paediatric Society guidelines for TBM treatment in children, consisting of daily isoniazid (7–15 mg/kg), rifampicin (10–20 mg/kg), pyrazinamide (30–40 mg/kg) and ethambutol (15–25 mg/kg) for a 2-month intensive phase, followed by a 10-month continuation phase of isoniazid and rifampicin at the same doses.<a href="#R5" class="usa-link" aria-describedby="R5"><sup>5 16</sup></a> All patients (including those weighing &gt;25 kg) received dispersible fixed-dose combinations of isoniazid/rifampicin/pyrazinamide at 50/75/150 mg, with addition of ethambutol in a separate tablet. All anti-TB drugs (Kimia Farma, Indonesia) were taken orally on an empty stomach under directly observed treatment. For unconscious patients, the drugs were dissolved in water delivered through a nasogastric tube and flushed afterwards. A rifampicin formulation of the same manufacturer has shown bioavailability in adults equal to the international reference.<a href="#R17" class="usa-link" aria-describedby="R17"><sup>17</sup></a> Patients were given adjunctive oral prednisone (2–4 mg/kg) for the first 4–8 weeks, tapered according to the national guidelines.<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a>
</p></section><section id="s2-3"><h3 class="pmc_sec_title">PK assessments</h3>
<p>PK sampling was performed on days 2±1 and 10±1 of treatment. Serial venous blood samples were collected at 0, 1, 2, 4 and 8 hours postdose; one CSF sample was also collected at 0–2, 3–5 or 6–8 hours postdose. Patients had an overnight fast from 23:00 hours on the day preceding PK assessments until 2 hours after drug administration. Bioanalysis was performed using a validated ultra-performance liquid chromatography method.<a href="#R18" class="usa-link" aria-describedby="R18"><sup>18</sup></a> PK parameters were assessed non-compartmentally using the PKNCA package V.0.9.4 in R for Windows. Main PK parameters were area under the plasma concentration–time curve during the daily dosing interval (AUC<sub>0–24</sub>), peak plasma concentration (<em>C</em>
<sub>max</sub>) and CSF concentration (<em>C</em>
<sub>CSF0–8</sub>). Further details are given in <a href="#SP1" class="usa-link">online supplemental appendix 1</a>.</p>
<section class="sm xbox font-sm" id="SP1"><div class="caption p"><span>Supplementary data</span></div>
<p>
<a href="/articles/instance/8685623/bin/archdischild-2020-321426supp001.pdf" class="usa-link" id="SS1">archdischild-2020-321426supp001.pdf</a><sup> (518.1KB, pdf) </sup>
</p></section></section><section id="s2-4"><h3 class="pmc_sec_title">Follow-up and clinical responses</h3>
<p>Inpatient assessments were performed on days 3, 7, 10 and 14 of treatment, including physical examinations, Glasgow Coma Scale, anthropometry, vital signs and complications such as hyponatraemia, decreased consciousness, new focal neurological signs and suspicion of DILI. Additional assessments were performed, if necessary. Liver function tests (LFTs) were measured on days 7 and 14 of treatment and were subsequently measured if symptomatic DILI was suspected. DILI was defined as an elevation of ALT/AST&gt;3× the ULN with symptoms of hepatotoxicity (eg, jaundice, vomiting, nausea and abdominal pain) or &gt;5× the ULN without the presence of symptoms.<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a> The severity of DILI was classified based on the common terminology criteria for adverse events (CTCAE V.5.0<a href="https://evs.nci.nih.gov/ftp1/CTCAE" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">; https://evs.nci.nih.gov/ftp1/CTCAE</a>). Outcome of hospitalisation included good recovery, moderate and severe disabilities, persistent vegetative state and death. Six-month mortality was monitored by phone calls.</p></section><section id="s2-5"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p>On the basis of the results from a previous study in adult patients with TBM,<a href="#R20" class="usa-link" aria-describedby="R20"><sup>20</sup></a> a minimum of 20 patients were judged to be sufficient to describe PK of anti-TB drugs. Actual target values for rifampicin AUC<sub>0–24</sub> in TBM (171 or 229 hour∙mg/L) were based on a PK/PD analysis in Indonesian adults with TBM,<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21</sup></a> and the proportion of patients achieving these target values was assessed. PK parameters on both sampling days were compared using a paired-sample t-test or Wilcoxon signed-rank test. Pearson correlation coefficients were used to assess the relationship between AUC<sub>0–24</sub>, <em>C</em>
<sub>max</sub> and <em>C</em>
<sub>CSF0–8</sub>. Predictors of drug exposures were evaluated using univariate and multivariate linear regression analyses; more details are given in <a href="#SP1" class="usa-link">online supplemental appendix 2</a>. AUC<sub>0–24</sub> and <em>C</em>
<sub>max</sub> values between DILI and non-DILI patients and between those who survived and died during the 6-month follow-up were compared using the Mann-Whitney U test. Data were analysed using SPSS Statistics (V.25.0; IBM).</p></section></section><section id="s3"><h2 class="pmc_sec_title">Results</h2>
<p>Between March 2018 and July 2019, 81 suspected cases of paediatric TBM (39 (48%) aged &lt;5 years) were screened, of whom 61 were excluded due to various reasons (<a href="#SP1" class="usa-link">online supplemental appendix 3</a>). Among 20 eligible HIV-negative patients with probable/possible TBM, 11 (55%) were female, 5 (25%) aged &lt;5 years and 12 (60%) had grade 2 TBM. Baseline characteristics of the study population are presented in <a href="#T1" class="usa-link">table 1</a>.</p>
<section class="tw xbox font-sm" id="T1"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Baseline characteristics and drug doses of Indonesian children with TBM</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<td align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</td>
<td align="left" valign="bottom" rowspan="1" colspan="1">Value</td>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total cases, n</td>
<td align="left" valign="top" rowspan="1" colspan="1">20</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Female sex (n (%))</td>
<td align="left" valign="top" rowspan="1" colspan="1">11 (55.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Age, years (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1">11.4 (4.4–14.7)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Age (n (%))</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> &lt;5 years</td>
<td align="left" valign="top" rowspan="1" colspan="1">5 (25.0)</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> 5–9 years</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (20.0)</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> 10–14 years</td>
<td align="left" valign="top" rowspan="1" colspan="1">6 (30.0)</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> 15–18 years</td>
<td align="left" valign="top" rowspan="1" colspan="1">5 (25.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">BCG-vaccinated (n (%))</td>
<td align="left" valign="top" rowspan="1" colspan="1">11 (55.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Nutritional status*</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Weight for age Z-score (median (IQR))†</td>
<td align="left" valign="top" rowspan="1" colspan="1">−2.08 (−3.06 to −1.32)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Height for age Z-score (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1">−2.10 (−2.44 to −1.21)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> BMI for age Z-score (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1">−2.22 (−2.98 to −1.02)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Head circumference, cm (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1">50.0 (45.6–52.2)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Upper arm circumference, cm (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1">16.2 (12.6–20.6)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Abdominal circumference, cm (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1">52.5 (46.7–58.2)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Malnourished, n (%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">14 (70.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Temperature, °C (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1">37.1 (37.0–37.8)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Chief complaint (n (%))</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Severe headache</td>
<td align="left" valign="top" rowspan="1" colspan="1">3 (15.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Seizures</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (20.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Decreased consciousness</td>
<td align="left" valign="top" rowspan="1" colspan="1">9 (45.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Others</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (20.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Diagnostic score (median (IQR))‡</td>
<td align="left" valign="top" rowspan="1" colspan="1">10.5 (10.0–12.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">GCS (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1">13.0 (11.0–15.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Chest radiography, suggestive TB (n (%))</td>
<td align="left" valign="top" rowspan="1" colspan="1">8 (40.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">TBM category</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Possible TBM</td>
<td align="left" valign="top" rowspan="1" colspan="1">2 (10.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Probable TBM</td>
<td align="left" valign="top" rowspan="1" colspan="1">18 (90.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">TBM grade (n (%))§</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Grade 1</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (20.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Grade 2</td>
<td align="left" valign="top" rowspan="1" colspan="1">12 (60.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Grade 3</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (20.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">CSF baselines (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Leucocytes, cells/µL</td>
<td align="left" valign="top" rowspan="1" colspan="1">88.0 (41.0–134.2)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> PMN, cells/µL</td>
<td align="left" valign="top" rowspan="1" colspan="1">20.5 (5.0–43.7)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> MN, cells/µL</td>
<td align="left" valign="top" rowspan="1" colspan="1">79.5 (56.2–95.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Protein, mg/dL</td>
<td align="left" valign="top" rowspan="1" colspan="1">176.9 (80.7–287.5)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">CSF/blood glucose ratio (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.17 (0.10–0.44)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">CSF smear microscopy (n (%))</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Negative</td>
<td align="left" valign="top" rowspan="1" colspan="1">15 (75.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Not tested</td>
<td align="left" valign="top" rowspan="1" colspan="1">5 (25.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Cerebral imaging, done (n (%))¶</td>
<td align="left" valign="top" rowspan="1" colspan="1">12 (60.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Abnormal</td>
<td align="left" valign="top" rowspan="1" colspan="1">11 (55.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">  Hydrocephalus</td>
<td align="left" valign="top" rowspan="1" colspan="1">7 (35.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">  Basal meningeal enhancement</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (20.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">  Brain oedema</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (20.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">  Midline shift</td>
<td align="left" valign="top" rowspan="1" colspan="1">2 (10.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">  Tuberculoma</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">  Infarct</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">  Intracerebral haemorrhage</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Normal</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">GeneXpert MTB/RIF testing (extraneural), done (n (%))**</td>
<td align="left" valign="top" rowspan="1" colspan="1">4 (20.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> M.<em>tb</em> detected, susceptible to rifampicin</td>
<td align="left" valign="top" rowspan="1" colspan="1">3 (15.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> M.<em>tb</em> not detected</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Blood test values (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Creatinine, mg/dL</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.3–0.6)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Albumin, g/dL</td>
<td align="left" valign="top" rowspan="1" colspan="1">3.2 (2.4–3.5)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Protein, g/dL</td>
<td align="left" valign="top" rowspan="1" colspan="1">7.6 (6.9–8.4)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Random blood glucose, mg/dL</td>
<td align="left" valign="top" rowspan="1" colspan="1">107.0 (102.0–119.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> AST, IU/L</td>
<td align="left" valign="top" rowspan="1" colspan="1">22.0 (16.0–33.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> ALT, IU/L</td>
<td align="left" valign="top" rowspan="1" colspan="1">16.0 (13.0–30.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Drug administration through NGT on PK1 (n (%))</td>
<td align="left" valign="top" rowspan="1" colspan="1">14 (70.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Drug administration through NGT on PK2 (n (%))</td>
<td align="left" valign="top" rowspan="1" colspan="1">4/12 (20.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Daily drug doses on PK1 (median (IQR))</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Isoniazid (mg/kg)</td>
<td align="left" valign="top" rowspan="1" colspan="1">8.9 (7.7–11.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Rifampicin (mg/kg)</td>
<td align="left" valign="top" rowspan="1" colspan="1">13.4 (11.6–16.4)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Pyrazinamide (mg/kg)</td>
<td align="left" valign="top" rowspan="1" colspan="1">26.7 (23.1–32.9)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Ethambutol (mg/kg)</td>
<td align="left" valign="top" rowspan="1" colspan="1">20.5 (19.1–21.6)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="T1_FN1"><p>*Anthropometric data were transformed into weight-for-age, height-for-age and BMI-for-age Z-scores based on the WHO standard reference populations using the R package ‘zscorer’ V.0.3.1. Malnutrition was defined as children aged &lt;5 years with weight-for-age or height-for-age Z-scores &lt;−2 SD and children aged ≥5 years with height-for-age or BMI-for-age Z-scores &lt;−2 SD.</p></div>
<div class="fn" id="T1_FN2"><p>†Weigh for age Z-score can only be calculated for nine children.</p></div>
<div class="fn" id="T1_FN3"><p>‡Diagnostic score was assessed using a uniform case definition criteria for TBM by Marais <em>et al</em>.<a href="#R15" class="usa-link" aria-describedby="R15"><sup>15</sup></a>
</p></div>
<div class="fn" id="T1_FN4"><p>§Severity of TBM was classified according to the modified British Medical Research Council grading system as 1 (GCS of 15 with no focal neurological signs), 2 (GCS of 11–14 or 15 with focal neurological signs) or 3 (GCS&lt;10).<a href="#R44" class="usa-link" aria-describedby="R44"><sup>44</sup></a>
</p></div>
<div class="fn" id="T1_FN5"><p>¶During hospitalisation, head computed tomographic scan was performed in 11 (55%) of 20 patients and head magnetic resonance imaging was performed in 1 (5%) of 20 patients.</p></div>
<div class="fn" id="T1_FN6"><p>**Three patients were susceptible to rifampicin using GeneXpert testing from gastric lavage sample, and one patient had no <em>M. tb</em> detected in sputum sample.</p></div>
<div class="fn" id="T1_FN7"><p>ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CSF, cerebrospinal fluid; GCS, Glasgow Coma Scale; MN, mononuclear cells; NGT, nasogastric tube; PK1 and PK2, first and second pharmacokinetic sampling assessments; PMN, polymorphonuclear cells; TBM, tuberculous meningitis.</p></div>
</div></section><p>Plasma concentration–time profiles of isoniazid, rifampicin and pyrazinamide are presented in <a href="#F1" class="usa-link">figure 1</a>. Geometric mean AUC<sub>0–24</sub> of isoniazid, rifampicin and pyrazinamide on day 2 was 18.5, 66.9 and 315.5 hour∙mg/L, respectively. Large interindividual variabilities were observed in AUC<sub>0–24</sub> and <em>C</em>
<sub>max</sub> of all drugs. None of the patients had achieved the target values of 229 or 171 hour∙mg/L for rifampicin AUC<sub>0–24</sub>. All patients had disproportionately lower rifampicin concentrations in CSF than in plasma (geometric mean <em>C</em>
<sub>CSF0–8</sub>: 0.3 and 0.1 mg/L on days 2 and 10, respectively). Isoniazid and pyrazinamide concentrations in CSF were relatively comparable to those in plasma. AUC<sub>0–24</sub> and <em>C</em>
<sub>max</sub> between both sampling days were not statistically different (<a href="#T2" class="usa-link">table 2</a>). Additional PK parameters are presented in <a href="#SP1" class="usa-link">online supplemental appendix 4</a>.</p>
<figure class="fig xbox font-sm" id="F1"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8685623_archdischild-2020-321426f01.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13c9/8685623/34199dc2adff/archdischild-2020-321426f01.jpg" loading="lazy" height="850" width="773" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pharmacokinetic profiles (drug concentration vs time curves) of isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA) in children and adolescents treated for tuberculous meningitis on days 2 and 10 of treatment. (A) INH in plasma; (B) RIF in plasma; (C) PZA in plasma; (D) INH in cerebrospinal fluid (CSF); (E) RIF in CSF; (F) PZA in CSF.</p></figcaption></figure><section class="tw xbox font-sm" id="T2"><h3 class="obj_head">Table 2.</h3>
<div class="caption p"><p>Summary of pharmacokinetic (PK) parameters of isoniazid, rifampicin and pyrazinamide among Indonesian children treated for TBM</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<td align="left" valign="bottom" rowspan="1" colspan="1">PK parameters</td>
<td align="left" valign="bottom" rowspan="1" colspan="1">First PK assessment (n=20)</td>
<td align="left" valign="bottom" rowspan="1" colspan="1">Second PK assessment (n=12)</td>
<td align="left" valign="bottom" rowspan="1" colspan="1">P value*</td>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Isoniazid</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> AUC<sub>0–24</sub> (h∙mg/L)</td>
<td align="center" valign="top" rowspan="1" colspan="1">18.5 (5.1–47.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">14.5 (5.9–44.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.888</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>max</sub> (mg/L)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.6 (1.0–10.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4.7 (2.5–13.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.366</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>CSF0–2</sub> (mg/L)†</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.4 (0.5–6.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.6 (1.2–2.5)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>CSF3–5</sub> (mg/L)†</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.6 (0.3–5.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.7 (0.6–5.0)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>CSF6–8</sub> (mg/L)†</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.3 (1.2–4.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.3 (1.9–2.8)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Rifampicin</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> AUC<sub>0–24</sub> (h∙mg/L)</td>
<td align="center" valign="top" rowspan="1" colspan="1">66.9 (21.7–118.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">71.8 (36.1–116.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.442</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>max</sub> (mg/L)</td>
<td align="center" valign="top" rowspan="1" colspan="1">9.4 (2.9–23.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">10.4 (5.7–23.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.499</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>CSF0–2</sub> (mg/L)†</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.2 (0.1–0.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.1 (0.1–0.1)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>CSF3–5</sub> (mg/L)†</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.3 (0.1–0.8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.1 (0.1–0.3)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>CSF6–8</sub> (mg/L)†</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.4 (0.1–1.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.2 (0.1–0.7)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Pyrazinamide</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> AUC<sub>0–24</sub> (h∙mg/L)</td>
<td align="center" valign="top" rowspan="1" colspan="1">315.5 (100.6–599.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">328.4 (143.3–1477.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.482</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>max</sub> (mg/L)</td>
<td align="center" valign="top" rowspan="1" colspan="1">37.7 (15.9–61.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">40.5 (22.7–88.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.350</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>CSF0–2</sub> (mg/L)†</td>
<td align="center" valign="top" rowspan="1" colspan="1">24.4 (11.1–54.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">25.6 (21.3–37.1)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>CSF3–5</sub> (mg/L)†</td>
<td align="center" valign="top" rowspan="1" colspan="1">30.0 (19.2–43.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">24.7 (15.9–38.1)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1"> <em>C</em>
<sub>CSF6–8</sub> (mg/L)†</td>
<td align="center" valign="top" rowspan="1" colspan="1">19.6 (7.2–37.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">39.4 (23.1–70.8)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="T2_FN1"><p>Data are presented as geometric mean (range). The first PK assessment was performed on day 2 of treatment and the second PK assessment was performed on day 10 of treatment.</p></div>
<div class="fn" id="T2_FN2"><p>*Paired-sample t-test on log-transformed data of 12 patients for whom PK data were available both at the first and second PK assessments.</p></div>
<div class="fn" id="T2_FN3"><p>†At the first PK assessment, 6, 7 and 7 CSF samples for each drug were available at 0–2 hours, 3–5 hours and 6–8 hours, respectively; and at the second PK assessment, 4, 4 and 3 CSF samples for each drug were available at 0–2 hours, 3–5 hours and 6–8 hours, respectively.</p></div>
<div class="fn" id="T2_FN4"><p>AUC<sub>0–24</sub>, area under the plasma concentration–time curve from 0 to 24 hours postdose; <em>C</em>
<sub>CSF0–8</sub>, drug concentration in cerebrospinal fluid during 0–8 hours postdose; <em>C</em>
<sub>max</sub>, peak plasma concentration; n/a, non-applicable; TBM, tuberculous meningitis.</p></div>
</div></section><p>For each drug, AUC<sub>0–24</sub> was highly correlated with <em>C</em>
<sub>max</sub> (<em>r<sub>s</sub>
</em>≥0.7; p&lt;0.001). AUC<sub>0–24</sub> and <em>C</em>
<sub>max</sub> were also correlated with <em>C</em>
<sub>CSF0–8</sub> (<em>r<sub>s</sub>
</em>≥0.5; p&lt;0.05) (<a href="#SP1" class="usa-link">online supplemental appendix 5</a>. Results of the univariate analyses for predictors of AUC<sub>0–24</sub>, <em>C</em>
<sub>max</sub> and <em>C</em>
<sub>CSF0–8</sub> are presented in <a href="#SP1" class="usa-link">online supplemental appendix 6</a>. In multivariate analyses, higher drug doses in mg/kg were associated with a larger increase in pyrazinamide <em>C</em>
<sub>max</sub> (p&lt;0.05); drug administration through a nasogastric tube was associated with a higher isoniazid AUC<sub>0–24</sub> (p&lt;0.01); and higher random blood glucose levels were associated with reduced pyrazinamide AUC<sub>0–24</sub>, <em>C</em>
<sub>max</sub> and <em>C</em>
<sub>CSF0–8</sub> (p&lt;0.01) (<a href="#T3" class="usa-link">table 3</a>).</p>
<section class="tw xbox font-sm" id="T3"><h3 class="obj_head">Table 3.</h3>
<div class="caption p"><p>Multivariate linear regression analysis of factors associated with AUC<sub>0–24</sub>, <em>C</em>
<sub>max</sub> and CSF concentrations of isoniazid, rifampicin and pyrazinamide in Indonesian children treated for TBM</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<td align="left" valign="bottom" rowspan="1" colspan="1"></td>
<td align="left" valign="bottom" rowspan="1" colspan="1">AUC<sub>0–24,</sub> hour∙mg/L<br>(B (95% CI))</td>
<td align="left" valign="bottom" rowspan="1" colspan="1">
<em>C</em>
<sub>max</sub>, mg/L<br>(B (95% CI))</td>
<td align="left" valign="bottom" rowspan="1" colspan="1">
<em>C</em>
<sub>CSF</sub>0–8, mg/L<br>(B (95% CI))</td>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Isoniazid</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Age, years</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.020 (−0.043 to 0.003)<sup>#</sup>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Random blood glucose, mg/dL</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.002 (−0.006 to 0.003)</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.004 (−0.009 to 0.001)</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.007 (−0.015 to 0.001)<sup>#</sup>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Drug dose, mg/kg</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.016 (−0.048 to 0.080)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.046 (−0.058 to 0.151)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Drug administration via NGT, no/yes</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.439 (0.143 to 0.735)**</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.130 (−0.160 to 0.420)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.289 (−0.197 to 0.775)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Rifampicin</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Age, years</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.009 (−0.028 to 0.010)</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.008 (−0.029 to 0.012)</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.021 (−0.052 to 0.009)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Random blood glucose, mg/dL</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.003 (−0.007 to 0.001)</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.005 (−0.009 to −0.0003)*</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Drug dose, mg/kg</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.014 (−0.021 to 0.048)</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.030 (−0.030 to 0.091)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Drug administration via NGT, no/yes</td>
<td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.067 (−0.194 to 0.328)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.019 (−0.365 to 0.403)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Pyrazinamide</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Random blood glucose, mg/dL</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.006 (−0.010 to −0.003)**</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.003 (−0.005 to −0.001)**</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.006 (−0.010 to −0.003)**</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Drug dose, mg/kg</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.010 (−0.006 to 0.027)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.010 (0.001 to 0.020)*</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.010 (−0.006 to 0.027)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"> Drug administration via NGT, no/yes</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.068 (−0.293 to 0.156)</td>
<td align="left" valign="top" rowspan="1" colspan="1">0.036 (−0.095 to 0.167)</td>
<td align="left" valign="top" rowspan="1" colspan="1">−0.068 (−0.293 to 0.156)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="T3_FN1"><p>Data are presented as regression coefficients (B) and 95% CIs. <sup>#</sup>p&lt;0.1, *p&lt;0.05, **p&lt;0.01.</p></div>
<div class="fn" id="T3_FN2"><p>The total explained variance (R<sup>2</sup>) for isoniazid AUC<sub>0–24</sub>: 0.57, isoniazid <em>C</em>
<sub>max</sub>: 0.46, isoniazid <em>C</em>
<sub>CSF0–8</sub>: 0.45; rifampicin AUC<sub>0–24</sub>: 0.31, rifampicin <em>C</em>
<sub>max</sub>: 0.38, rifampicin <em>C</em>
<sub>CSF0–8</sub>: 0.33, pyrazinamide AUC<sub>0–24</sub>: 0.53, pyrazinamide <em>C</em>
<sub>max</sub>: 0.63 and pyrazinamide <em>C</em>
<sub>CSF0–8</sub>: 0.53.</p></div>
<div class="fn" id="T3_FN3"><p>AUC<sub>0–24</sub>, area under the plasma concentration–time curve from 0 to 24 hours postdose at the first PK assessment; <em>C</em>
<sub>CSF0–8</sub>, CSF concentrations during 0–8 hours postdose at the first PK assessment; CI, confidence interval; <em>C</em>
<sub>max</sub>, peak plasma concentration at the first PK assessment; n/a, non-applicable; NGT, nasogastric tube; TBM, tuberculous meningitis.</p></div>
</div></section><p>During hospitalisation, two patients had grade 2 and two patients had grade 3 DILI. Of these, one developed DILI after 1 week of treatment, two after 2 weeks and one after 4 weeks. Jaundice was observed in two patients: one with grade 2 and one with grade 3 DILI. Isoniazid, rifampicin and pyrazinamide were immediately stopped in these four patients. As per local guidelines, ethambutol was continued, with addition of streptomycin (15–40 mg/kg) for a maximum of 2 weeks. After the symptoms of DILI and liver enzymes had normalised, rifampicin and isoniazid were reintroduced gradually without any DILI recurrence. Pyrazinamide was completely stopped until the end of treatment. Isoniazid, rifampicin and pyrazinamide doses were slightly higher in patients with DILI but not statistically different from those without DILI (p&gt;0.05; <a href="#SP1" class="usa-link">online supplemental appendix 7</a>). AUC<sub>0–24</sub> of isoniazid, rifampicin and pyrazinamide, along with <em>C</em>
<sub>max</sub> of isoniazid and pyrazinamide on day 10 were significantly higher in patients with DILI than those without DILI (p&lt;0.05) (<a href="#F2" class="usa-link">figure 2</a>; <a href="#SP1" class="usa-link">online supplemental appendix 7</a>).</p>
<figure class="fig xbox font-sm" id="F2"><h3 class="obj_head">Figure 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8685623_archdischild-2020-321426f02.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13c9/8685623/383a79cf75af/archdischild-2020-321426f02.jpg" loading="lazy" height="850" width="773" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pharmacokinetic profiles of isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA) on day 10 of tuberculous meningitis treatment in children and adolescents who developed antituberculosis drug-induced liver-injury (DILI, n=3*) and those without DILI (n=9). (A) INH plasma concentration vs time curve; (B) RIF plasma concentration vs time curve; (C) PZA plasma concentration vs time curve; (D) INH area under the concentration–time curve during the dosing interval (AUC<sub>0–24</sub>); (E) RIF AUC<sub>0–24</sub>; (F) PZA AUC<sub>0–24</sub>. Box plots represent medians with IQRs; lower and upper whiskers represent first and fourth quartiles, respectively. *Of four patients with DILI, one who developed DILI on day 7 of treatment did not have INH, RIF and PZA concentrations measured on day 10 because the drugs had been temporarily stopped due to DILI.</p></figcaption></figure><p>At hospital discharge, 10 patients had good recovery, 2 were moderately disabled, 2 were severely disabled and 6 died due to increased intracranial pressure (n=2), intracerebral haemorrhage (n=1), septic shock (n=1), respiratory failure (n=1) and hospital-acquired pneumonia (n=1). Within the 6-month follow-up, another patient died of unknown cause and the remaining 13 patients survived including those who previously developed DILI. Post-mortem autopsy was unavailable to provide accurate causes of death. AUC<sub>0–24</sub>, <em>C</em>
<sub>max</sub> and <em>C</em>
<sub>CSF0–8</sub> of isoniazid, rifampicin and pyrazinamide were not statistically different between patients who survived and died within the 6-month follow-up.</p></section><section id="s4"><h2 class="pmc_sec_title">Discussion</h2>
<p>This study presents important information on plasma and CSF concentrations of first-line anti-TB drugs in children and adolescents with TBM from Indonesia. Our average AUC<sub>0–24</sub> values on day 2 of treatment compared with those reported in Indonesian adults with TBM were relatively similar for isoniazid (18.5 vs 16.4 hour∙mg/L),<a href="#R22" class="usa-link" aria-describedby="R22"><sup>22</sup></a> were higher for rifampicin (66.9 vs 53.5 hour∙mg/L)<a href="#R20" class="usa-link" aria-describedby="R20"><sup>20</sup></a> and were lower for pyrazinamide (315.5 vs 709 hour∙mg/L).<a href="#R23" class="usa-link" aria-describedby="R23"><sup>23</sup></a> Our results showed large interindividual variabilities in drug exposures, which are in agreement with the literature and might be enhanced by PK changes in critically ill patients.<a href="#R24" class="usa-link" aria-describedby="R24"><sup>24 25</sup></a> Furthermore, the wide age range included in this study from infants to adolescents, and the small sample size, might contribute to these large variabilities. Although none of our patients had diabetes mellitus, higher blood glucose levels were found to be associated with decreased pyrazinamide exposures. A hyperglycaemic condition may have reduced gastric mucosal blood flow and gastric acid secretion,<a href="#R26" class="usa-link" aria-describedby="R26"><sup>26</sup></a> which resulted in decreased absorption of anti-TB drugs.</p>
<p>The low rifampicin CSF concentration has been reported in Vietnamese children<a href="#R11" class="usa-link" aria-describedby="R11"><sup>11</sup></a> and in Indonesian adults with TBM.<a href="#R18" class="usa-link" aria-describedby="R18"><sup>18 20 27</sup></a> Likely the high plasma protein binding and blood-CSF/brain barrier efflux pumps can explain this low CSF rifampicin concentration.<a href="#R28" class="usa-link" aria-describedby="R28"><sup>28</sup></a> The bactericidal effect of such a low concentration, when compared with the minimum inhibitory concentration (MIC) of this drug against <em>M. tuberculosis</em>, is likely to be limited if we use plasma-derived <em>f</em>AUC/MIC or <em>fC</em>
<sub>max</sub>/MIC targets. In adults, a 33% higher dose of intravenous rifampicin resulted in a threefold increase in plasma and CSF exposures compared with the standard dose of oral rifampicin.<a href="#R27" class="usa-link" aria-describedby="R27"><sup>27</sup></a> Threefold and fivefold increases in plasma exposure with proportional increases in CSF concentrations were also observed in adults given double and triple doses of oral rifampicin.<a href="#R20" class="usa-link" aria-describedby="R20"><sup>20</sup></a> It seems that efflux pumps may be saturable and CSF rifampicin concentrations can be enhanced by increasing the dose. In South African children, short-course intensified TBM treatment with isoniazid (20 mg/kg), rifampicin (20 mg/kg), pyrazinamide (40 mg/kg) and ethionamide (20 mg/kg) was found to be safe and effective.<a href="#R12" class="usa-link" aria-describedby="R12"><sup>12</sup></a> Intensified regimens containing high-dose rifampicin and other anti-TB drugs with better CSF penetration (eg, fluoroquinolones and ethionamide), along with ancillary treatment beyond corticosteroids such as targeted anti-inflammatory drugs (eg, aspirin, thalidomide and tumour necrosis factor-alpha antibodies), need further evaluation.<a href="#R12" class="usa-link" aria-describedby="R12"><sup>12 29</sup></a>
</p>
<p>Serious adverse events in children during TB treatment are rare although severe hepatotoxic events were occasionally reported.<a href="#R14" class="usa-link" aria-describedby="R14"><sup>14 30</sup></a> In a review by Donald,<a href="#R14" class="usa-link" aria-describedby="R14"><sup>14</sup></a> abnormal LFTs and jaundice were recorded, respectively, in 53% and in 10% of children during TBM therapy. In Indonesian settings, DILI frequently occurred in children during the first 2 months of TB therapy,<a href="#R31" class="usa-link" aria-describedby="R31"><sup>31 32</sup></a> with most of them being treated for TBM.<a href="#R31" class="usa-link" aria-describedby="R31"><sup>31</sup></a> The reason why patients with TBM are more likely to develop DILI is unclear but could be related to the severity of the underlying disease.<a href="#R33" class="usa-link" aria-describedby="R33"><sup>33</sup></a> Of note, this hepatotoxic event could have been the result of hepatic adaptation.<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a> The temporary use of streptomycin in this study could not be regarded as an effective treatment.<a href="#R10" class="usa-link" aria-describedby="R10"><sup>10 34</sup></a> Better management of DILI in children (including criteria to continue treatment in severe conditions and drug reintroduction regimens) is needed.</p>
<p>Data on the relationship between DILI and anti-TB drug exposures in children are lacking.<a href="#R14" class="usa-link" aria-describedby="R14"><sup>14</sup></a> In Chinese and Indian adults with PTB/extrapulmonary TB, higher isoniazid and rifampicin exposures were associated with an increased risk of DILI.<a href="#R35" class="usa-link" aria-describedby="R35"><sup>35 36</sup></a> High-dose rifampicin was not associated with an increase in DILI when administered to Tanzanian and South-African adults with PTB.<a href="#R37" class="usa-link" aria-describedby="R37"><sup>37</sup></a> In Indonesian adult patients with TBM, hepatotoxicity was not related to rifampicin exposure<a href="#R20" class="usa-link" aria-describedby="R20"><sup>20 27</sup></a> and was equally distributed between rifampicin standard-dose and high-dose groups.<a href="#R18" class="usa-link" aria-describedby="R18"><sup>18 20 27</sup></a> It should be acknowledged that neither the current study nor the previous studies in Indonesian adults<a href="#R18" class="usa-link" aria-describedby="R18"><sup>18 20 27</sup></a> were powered to test for an association between drug levels and DILI. Our findings on DILI in children with TBM warrant further investigation as DILI has clinical implications in increasing patient morbidity/mortality.<a href="#R38" class="usa-link" aria-describedby="R38"><sup>38</sup></a> The risk of DILI with increased drug dosages requires consideration, but it should be balanced against the need to ensure optimal treatment of a life-threatening illness like TBM.<a href="#R29" class="usa-link" aria-describedby="R29"><sup>29 39</sup></a> Combining therapeutic drug monitoring as a decisive tool for TB treatment,<a href="#R40" class="usa-link" aria-describedby="R40"><sup>40</sup></a> and regular monitoring of LFTs,<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a> might benefit to ensure drug efficacy without causing toxicity.</p>
<p>Our study has some limitations. Conducting intensive PK studies in children is challenging. Ideally, multiple CSF samples are required to assess CSF-to-plasma ratio for total drug exposure.<a href="#R41" class="usa-link" aria-describedby="R41"><sup>41</sup></a> Although we were able to collect two PK curves with a modest number of plasma samples, only one CSF sample per patient could be collected. As a result, AUC<sub>0–24</sub> and <em>C</em>
<sub>max</sub> in CSF could not be determined. None of our patients had definite TBM because mycobacterial confirmation is known to be a significant challenge in children, due to the paucibacillary nature of the disease and low CSF volumes available for diagnostic analysis.<a href="#R42" class="usa-link" aria-describedby="R42"><sup>42</sup></a> Relatively few young children who may be considered most at risk for being underdosed were included in this study. Our results pointed out, however, no difference in drug exposure between younger and older children. Of note, our population was not representative of the total paediatric TBM patients diagnosed over the study period. Due to the small sample size, our findings on predictors of exposure to anti-TB drugs and the relationship of drug exposures with DILI and 6-month mortality should be interpreted with caution. It could be of value to collect data on drug exposure and pathogen susceptibility in a large cohort to overcome the limitations of small-scale PK studies.<a href="#R43" class="usa-link" aria-describedby="R43"><sup>43</sup></a>
</p>
<p>In conclusion, suboptimal plasma and CSF rifampicin concentrations were observed in all patients, and there is an urgent need to increase the rifampicin dose in children and adolescents with TBM. Intensified regimens containing anti-TB drugs with better CSF penetration, along with other ancillary treatment for paediatric TBM, warrant further evaluation. The association between higher isoniazid, rifampicin and pyrazinamide concentrations and the development of DILI needs confirmatory studies.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>We would like to thank the director of Hasan Sadikin Hospital for accommodating the research. We would also like to thank all the patients for their participation in the study, as well as Yuanita Gunawan, Sheila Sumargo, Nadytia Kusumadjayanti and Aulia Rahman for monitoring the patients and data recording.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn15"><p>RR and FG contributed equally.</p></div>
<div class="fn p" id="fn16"><p><strong>Contributors:</strong> RR was the principal investigator. RR, VY, IP, ARG, and HMN contributed to conception and design of the study. VY performed PK sampling and bioanalyses of anti-TB drugs under RR supervision. FG performed data analyses and created tables and figures. RR, FG, VY, IP, ARG, REA, BW, J-WCA and HMN interpreted the results. FG drafted the manuscript under the supervision of RR, REA, BW and J-WCA. All authors critically revised the manuscript for important intellectual content and approved the final version of the manuscript.</p></div>
<div class="fn p" id="fn17"><p><strong>Funding:</strong> This work was supported by the Universitas Padjadjaran through the Academic Leadership Grant and by the University of Groningen through the Indonesia Endowment Fund for Education Scholarship (LPDP; 201711220412046).</p></div>
<div class="fn p" id="fn18"><p><strong>Competing interests:</strong> None declared.</p></div>
<div class="fn p" id="fn19"><p><strong>Provenance and peer review:</strong> Not commissioned; externally peer reviewed.</p></div>
<div class="fn p" id="fn20"><p><strong>Supplemental material:</strong> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></div>
</div></section><section id="sec18"><h2 class="pmc_sec_title">Data availability statement</h2>
<p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></section><section id="sec19"><h2 class="pmc_sec_title">Ethics statements</h2>
<section id="sec20"><h3 class="pmc_sec_title">Patient consent for publication</h3>
<p>Not required.</p></section><section id="sec21"><h3 class="pmc_sec_title">Ethics approval</h3>
<p>Research approval was granted by the Independent Ethics Committee, Faculty of Medicine, Universitas Padjadjaran (No: LB.04.01/A05/EC/029/II/2018).</p></section></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="R1">
<span class="label">1.</span><cite>
World Health Organization (WHO) . Global tuberculosis report 2020, 2020. Available: <a href="https://www.who.int/publications/i/item/9789240013131" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.who.int/publications/i/item/9789240013131</a>
</cite>
</li>
<li id="R2">
<span class="label">2.</span><cite>
Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis
2014;14:947–57. 10.1016/S1473-3099(14)70852-7
</cite> [<a href="https://doi.org/10.1016/S1473-3099(14)70852-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25108337/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Infect%20Dis&amp;title=Treatment%20outcomes%20of%20childhood%20tuberculous%20meningitis:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=14&amp;publication_year=2014&amp;pages=947-57&amp;pmid=25108337&amp;doi=10.1016/S1473-3099(14)70852-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R3">
<span class="label">3.</span><cite>
Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol
2017;13:581–98. 10.1038/nrneurol.2017.120
</cite> [<a href="https://doi.org/10.1038/nrneurol.2017.120" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28884751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Neurol&amp;title=Tuberculous%20meningitis&amp;volume=13&amp;publication_year=2017&amp;pages=581-98&amp;pmid=28884751&amp;doi=10.1038/nrneurol.2017.120&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R4">
<span class="label">4.</span><cite>
World Health Organization (WHO) . Rapid advice: treatment of tuberculosis in children, 2010. Available: <a href="https://apps.who.int/iris/handle/10665/44444" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://apps.who.int/iris/handle/10665/44444</a>
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/26269860/" class="usa-link">PubMed</a>]</li>
<li id="R5">
<span class="label">5.</span><cite>
World Health Organization (WHO) . Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd edn. World Health Organization, 2014. <a href="https://www.who.int/tb/publications/childtb_guidelines/en/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.who.int/tb/publications/childtb_guidelines/en/</a>
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/24999516/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=Guidance%20for%20national%20tuberculosis%20programmes%20on%20the%20management%20of%20tuberculosis%20in%20children&amp;publication_year=2014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R6">
<span class="label">6.</span><cite>
Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health organization recommendations. Antimicrob Agents Chemother
2011;55:5560–7. 10.1128/AAC.05429-11
</cite> [<a href="https://doi.org/10.1128/AAC.05429-11" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3232790/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21968358/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob%20Agents%20Chemother&amp;title=Pharmacokinetics%20of%20isoniazid,%20rifampin,%20and%20pyrazinamide%20in%20children%20younger%20than%20two%20years%20of%20age%20with%20tuberculosis:%20evidence%20for%20implementation%20of%20revised%20World%20Health%20organization%20recommendations&amp;volume=55&amp;publication_year=2011&amp;pages=5560-7&amp;pmid=21968358&amp;doi=10.1128/AAC.05429-11&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R7">
<span class="label">7.</span><cite>
Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. Antimicrob Agents Chemother
2016;60:2171–9. 10.1128/AAC.02600-15
</cite> [<a href="https://doi.org/10.1128/AAC.02600-15" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4808214/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26810651/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob%20Agents%20Chemother&amp;title=Pharmacokinetics%20of%20rifampin,%20isoniazid,%20pyrazinamide,%20and%20ethambutol%20in%20infants%20dosed%20according%20to%20revised%20WHO-recommended%20treatment%20guidelines&amp;volume=60&amp;publication_year=2016&amp;pages=2171-9&amp;pmid=26810651&amp;doi=10.1128/AAC.02600-15&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R8">
<span class="label">8.</span><cite>
Horita Y, Alsultan A, Kwara A, et al. Evaluation of the adequacy of WHO revised dosages of the first-line antituberculosis drugs in children with tuberculosis using population pharmacokinetic modeling and simulations. Antimicrob Agents Chemother
2018;62:e00008–18. 10.1128/AAC.00008-18
</cite> [<a href="https://doi.org/10.1128/AAC.00008-18" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6125554/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29914960/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob%20Agents%20Chemother&amp;title=Evaluation%20of%20the%20adequacy%20of%20WHO%20revised%20dosages%20of%20the%20first-line%20antituberculosis%20drugs%20in%20children%20with%20tuberculosis%20using%20population%20pharmacokinetic%20modeling%20and%20simulations&amp;volume=62&amp;publication_year=2018&amp;pages=e00008-18&amp;pmid=29914960&amp;doi=10.1128/AAC.00008-18&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R9">
<span class="label">9.</span><cite>
Dayal R, Singh Y, Agarwal D, et al. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status. Arch Dis Child
2018;103:1150–4. 10.1136/archdischild-2017-313910
</cite> [<a href="https://doi.org/10.1136/archdischild-2017-313910" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29514812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Dis%20Child&amp;title=Pharmacokinetic%20study%20of%20isoniazid%20and%20pyrazinamide%20in%20children:%20impact%20of%20age%20and%20nutritional%20status&amp;volume=103&amp;publication_year=2018&amp;pages=1150-4&amp;pmid=29514812&amp;doi=10.1136/archdischild-2017-313910&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R10">
<span class="label">10.</span><cite>
Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis
2010;90:279–92. 10.1016/j.tube.2010.07.002
</cite> [<a href="https://doi.org/10.1016/j.tube.2010.07.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20709598/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tuberculosis&amp;title=Cerebrospinal%20fluid%20concentrations%20of%20antituberculosis%20agents%20in%20adults%20and%20children&amp;volume=90&amp;publication_year=2010&amp;pages=279-92&amp;pmid=20709598&amp;doi=10.1016/j.tube.2010.07.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R11">
<span class="label">11.</span><cite>
Pouplin T, Bang ND, Toi PV, et al. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. BMC Infect Dis
2016;16:144. 10.1186/s12879-016-1470-x
</cite> [<a href="https://doi.org/10.1186/s12879-016-1470-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4818938/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27039088/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Infect%20Dis&amp;title=Na%C3%AFve-pooled%20pharmacokinetic%20analysis%20of%20pyrazinamide,%20isoniazid%20and%20rifampicin%20in%20plasma%20and%20cerebrospinal%20fluid%20of%20Vietnamese%20children%20with%20tuberculous%20meningitis&amp;volume=16&amp;publication_year=2016&amp;pages=144&amp;pmid=27039088&amp;doi=10.1186/s12879-016-1470-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R12">
<span class="label">12.</span><cite>
van Toorn R, Schaaf HS, Laubscher JA, et al. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J
2014;33:248–52. 10.1097/INF.0000000000000065
</cite> [<a href="https://doi.org/10.1097/INF.0000000000000065" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24168978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pediatr%20Infect%20Dis%20J&amp;title=Short%20intensified%20treatment%20in%20children%20with%20drug-susceptible%20tuberculous%20meningitis&amp;volume=33&amp;publication_year=2014&amp;pages=248-52&amp;pmid=24168978&amp;doi=10.1097/INF.0000000000000065&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R13">
<span class="label">13.</span><cite>
Swaminathan S, Pasipanodya JG, Ramachandran G, et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread Crumb trails in random forests. Clin Infect Dis
2016;63:S63–74. 10.1093/cid/ciw471
</cite> [<a href="https://doi.org/10.1093/cid/ciw471" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5064152/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27742636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Drug%20concentration%20thresholds%20predictive%20of%20therapy%20failure%20and%20death%20in%20children%20with%20tuberculosis:%20bread%20Crumb%20trails%20in%20random%20forests&amp;volume=63&amp;publication_year=2016&amp;pages=S63-74&amp;pmid=27742636&amp;doi=10.1093/cid/ciw471&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R14">
<span class="label">14.</span><cite>
Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep
2011;3:e16. 10.4081/pr.2011.e16
</cite> [<a href="https://doi.org/10.4081/pr.2011.e16" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3133498/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21772953/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pediatr%20Rep&amp;title=Antituberculosis%20drug-induced%20hepatotoxicity%20in%20children&amp;volume=3&amp;publication_year=2011&amp;pages=e16&amp;pmid=21772953&amp;doi=10.4081/pr.2011.e16&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R15">
<span class="label">15.</span><cite>
Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis
2010;10:803–12. 10.1016/S1473-3099(10)70138-9
</cite> [<a href="https://doi.org/10.1016/S1473-3099(10)70138-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20822958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Infect%20Dis&amp;title=Tuberculous%20meningitis:%20a%20uniform%20case%20definition%20for%20use%20in%20clinical%20research&amp;volume=10&amp;publication_year=2010&amp;pages=803-12&amp;pmid=20822958&amp;doi=10.1016/S1473-3099(10)70138-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R16">
<span class="label">16.</span><cite>
Rahajoe NN, Nawas A, Setyanto DB. Buku petunjuk teknis manajemen dan tatalaksana TB anak [National guideline on the management of tuberculosis in children]. Jakarta: Ministry of Health of the Republic of Indonesia, 2016.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Buku%20petunjuk%20teknis%20manajemen%20dan%20tatalaksana%20TB%20anak%20%5BNational%20guideline%20on%20the%20management%20of%20tuberculosis%20in%20children%5D&amp;publication_year=2016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R17">
<span class="label">17.</span><cite>
van Crevel R, Nelwan RH, Borst F, et al. Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers. Int J Tuberc Lung Dis
2004;8:500–3.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/15141745/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Tuberc%20Lung%20Dis&amp;title=Bioavailability%20of%20rifampicin%20in%20Indonesian%20subjects:%20a%20comparison%20of%20different%20local%20drug%20manufacturers&amp;volume=8&amp;publication_year=2004&amp;pages=500-3&amp;pmid=15141745&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R18">
<span class="label">18.</span><cite>
Yunivita V, Dian S, Ganiem AR, et al. Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. Int J Antimicrob Agents
2016;48:415–21. 10.1016/j.ijantimicag.2016.06.016
</cite> [<a href="https://doi.org/10.1016/j.ijantimicag.2016.06.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27526979/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Antimicrob%20Agents&amp;title=Pharmacokinetics%20and%20safety/tolerability%20of%20higher%20oral%20and%20intravenous%20doses%20of%20rifampicin%20in%20adult%20tuberculous%20meningitis%20patients&amp;volume=48&amp;publication_year=2016&amp;pages=415-21&amp;pmid=27526979&amp;doi=10.1016/j.ijantimicag.2016.06.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R19">
<span class="label">19.</span><cite>
Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med
2006;174:935–52. 10.1164/rccm.200510-1666ST
</cite> [<a href="https://doi.org/10.1164/rccm.200510-1666ST" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17021358/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Respir%20Crit%20Care%20Med&amp;title=An%20official%20ATS%20statement:%20hepatotoxicity%20of%20antituberculosis%20therapy&amp;volume=174&amp;publication_year=2006&amp;pages=935-52&amp;pmid=17021358&amp;doi=10.1164/rccm.200510-1666ST&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R20">
<span class="label">20.</span><cite>
Dian S, Yunivita V, Ganiem AR, et al. Double-blind, randomized, placebo-controlled phase II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis. Antimicrob Agents Chemother
2018;62:e01014–8. 10.1128/AAC.01014-18
</cite> [<a href="https://doi.org/10.1128/AAC.01014-18" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6256787/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30224533/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob%20Agents%20Chemother&amp;title=Double-blind,%20randomized,%20placebo-controlled%20phase%20II%20dose-finding%20study%20to%20evaluate%20high-dose%20rifampin%20for%20tuberculous%20meningitis&amp;volume=62&amp;publication_year=2018&amp;pages=e01014-8&amp;pmid=30224533&amp;doi=10.1128/AAC.01014-18&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R21">
<span class="label">21.</span><cite>
Svensson EM, Dian S, Te Brake L, et al. Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials. Clin Infect Dis
2020;71:1817–23. 10.1093/cid/ciz1071
</cite> [<a href="https://doi.org/10.1093/cid/ciz1071" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7643733/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31665299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Model-based%20meta-analysis%20of%20rifampicin%20exposure%20and%20mortality%20in%20Indonesian%20tuberculous%20meningitis%20trials&amp;volume=71&amp;publication_year=2020&amp;pages=1817-23&amp;pmid=31665299&amp;doi=10.1093/cid/ciz1071&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R22">
<span class="label">22.</span><cite>
Yunivita V, Ruslami R, Dian S. Pharmacokinetics of isoniazid and the effect of acetylator status in Indonesian tuberculous meningitis patients. In: International workshop on pharmacology of TB drugs. Atlanta, 2017.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=International%20workshop%20on%20pharmacology%20of%20TB%20drugs&amp;publication_year=2017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R23">
<span class="label">23.</span><cite>
Stemkens R, Litjens CHC, Dian S, et al. Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment. Int J Antimicrob Agents
2019;54:371–4. 10.1016/j.ijantimicag.2019.06.010
</cite> [<a href="https://doi.org/10.1016/j.ijantimicag.2019.06.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31202922/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Antimicrob%20Agents&amp;title=Pharmacokinetics%20of%20pyrazinamide%20during%20the%20initial%20phase%20of%20tuberculous%20meningitis%20treatment&amp;volume=54&amp;publication_year=2019&amp;pages=371-4&amp;pmid=31202922&amp;doi=10.1016/j.ijantimicag.2019.06.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R24">
<span class="label">24.</span><cite>
Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev
2014;77:3–11. 10.1016/j.addr.2014.07.006
</cite> [<a href="https://doi.org/10.1016/j.addr.2014.07.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25038549/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Adv%20Drug%20Deliv%20Rev&amp;title=The%20effect%20of%20pathophysiology%20on%20pharmacokinetics%20in%20the%20critically%20ill%20patient--concepts%20appraised%20by%20the%20example%20of%20antimicrobial%20agents&amp;volume=77&amp;publication_year=2014&amp;pages=3-11&amp;pmid=25038549&amp;doi=10.1016/j.addr.2014.07.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R25">
<span class="label">25.</span><cite>
Felton TW, Hope WW, Roberts JA. How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?
Diagn Microbiol Infect Dis
2014;79:441–7. 10.1016/j.diagmicrobio.2014.04.007
</cite> [<a href="https://doi.org/10.1016/j.diagmicrobio.2014.04.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24985764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagn%20Microbiol%20Infect%20Dis&amp;title=How%20severe%20is%20antibiotic%20pharmacokinetic%20variability%20in%20critically%20ill%20patients%20and%20what%20can%20be%20done%20about%20it?&amp;volume=79&amp;publication_year=2014&amp;pages=441-7&amp;pmid=24985764&amp;doi=10.1016/j.diagmicrobio.2014.04.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R26">
<span class="label">26.</span><cite>
Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet
2012;51:481–99. 10.1007/BF03261926
</cite> [<a href="https://doi.org/10.1007/BF03261926" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22668340/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacokinet&amp;title=Effect%20of%20diabetes%20mellitus%20on%20pharmacokinetic%20and%20pharmacodynamic%20properties%20of%20drugs&amp;volume=51&amp;publication_year=2012&amp;pages=481-99&amp;pmid=22668340&amp;doi=10.1007/BF03261926&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R27">
<span class="label">27.</span><cite>
Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis
2013;13:27–35. 10.1016/S1473-3099(12)70264-5
</cite> [<a href="https://doi.org/10.1016/S1473-3099(12)70264-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23103177/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Infect%20Dis&amp;title=Intensified%20regimen%20containing%20rifampicin%20and%20moxifloxacin%20for%20tuberculous%20meningitis:%20an%20open-label,%20randomised%20controlled%20phase%202%20trial&amp;volume=13&amp;publication_year=2013&amp;pages=27-35&amp;pmid=23103177&amp;doi=10.1016/S1473-3099(12)70264-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R28">
<span class="label">28.</span><cite>
Te Brake LHM, de Knegt GJ, de Steenwinkel JE, et al. The role of efflux pumps in tuberculosis treatment and their promise as a target in drug development: unraveling the black box. Annu Rev Pharmacol Toxicol
2018;58:271–91. 10.1146/annurev-pharmtox-010617-052438
</cite> [<a href="https://doi.org/10.1146/annurev-pharmtox-010617-052438" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28715978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu%20Rev%20Pharmacol%20Toxicol&amp;title=The%20role%20of%20efflux%20pumps%20in%20tuberculosis%20treatment%20and%20their%20promise%20as%20a%20target%20in%20drug%20development:%20unraveling%20the%20black%20box&amp;volume=58&amp;publication_year=2018&amp;pages=271-91&amp;pmid=28715978&amp;doi=10.1146/annurev-pharmtox-010617-052438&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R29">
<span class="label">29.</span><cite>
Huynh J, Thwaites G, Marais BJ, et al. Tuberculosis treatment in children: the changing landscape. Paediatr Respir Rev
2020;36:33–43. 10.1016/j.prrv.2020.02.002
</cite> [<a href="https://doi.org/10.1016/j.prrv.2020.02.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32241748/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Paediatr%20Respir%20Rev&amp;title=Tuberculosis%20treatment%20in%20children:%20the%20changing%20landscape&amp;volume=36&amp;publication_year=2020&amp;pages=33-43&amp;pmid=32241748&amp;doi=10.1016/j.prrv.2020.02.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R30">
<span class="label">30.</span><cite>
Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop Med Int Health
2009;14:1329–37. 10.1111/j.1365-3156.2009.02375.x
</cite> [<a href="https://doi.org/10.1111/j.1365-3156.2009.02375.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19735381/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trop%20Med%20Int%20Health&amp;title=Toxicity%20of%20first-line%20drugs%20for%20treatment%20of%20tuberculosis%20in%20children:%20review&amp;volume=14&amp;publication_year=2009&amp;pages=1329-37&amp;pmid=19735381&amp;doi=10.1111/j.1365-3156.2009.02375.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R31">
<span class="label">31.</span><cite>
Gafar F, Arifin H, Jurnalis YD, et al. Antituberculosis drug-induced liver injury in children: incidence and risk factors during the two-month intensive phase of therapy. Pediatr Infect Dis J
2019;38:50–3. 10.1097/INF.0000000000002192
</cite> [<a href="https://doi.org/10.1097/INF.0000000000002192" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30234790/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pediatr%20Infect%20Dis%20J&amp;title=Antituberculosis%20drug-induced%20liver%20injury%20in%20children:%20incidence%20and%20risk%20factors%20during%20the%20two-month%20intensive%20phase%20of%20therapy&amp;volume=38&amp;publication_year=2019&amp;pages=50-3&amp;pmid=30234790&amp;doi=10.1097/INF.0000000000002192&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R32">
<span class="label">32.</span><cite>
Nataprawira HM, Hannah RA, Kartika HH, et al. Hospitalized pediatric antituberculosis drug induced hepatotoxicity: experience of an Indonesian referral hospital. Asian Pac J Trop Dis
2017;7:276–9. 10.12980/apjtd.7.2017D6-402
</cite> [<a href="https://doi.org/10.12980/apjtd.7.2017D6-402" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Asian%20Pac%20J%20Trop%20Dis&amp;title=Hospitalized%20pediatric%20antituberculosis%20drug%20induced%20hepatotoxicity:%20experience%20of%20an%20Indonesian%20referral%20hospital&amp;volume=7&amp;publication_year=2017&amp;pages=276-9&amp;doi=10.12980/apjtd.7.2017D6-402&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R33">
<span class="label">33.</span><cite>
Kumar M, Kalita J, Tripathi A, et al. Is drug-induced hepatitis related to the severity of tuberculous meningitis?
Trans R Soc Trop Med Hyg
2017;111:520–6. 10.1093/trstmh/try006
</cite> [<a href="https://doi.org/10.1093/trstmh/try006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29438557/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trans%20R%20Soc%20Trop%20Med%20Hyg&amp;title=Is%20drug-induced%20hepatitis%20related%20to%20the%20severity%20of%20tuberculous%20meningitis?&amp;volume=111&amp;publication_year=2017&amp;pages=520-6&amp;pmid=29438557&amp;doi=10.1093/trstmh/try006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R34">
<span class="label">34.</span><cite>
Seddon JA, Schaaf HS, Marais BJ, et al. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. Lancet Respir Med
2018;6:662–4. 10.1016/S2213-2600(18)30329-1
</cite> [<a href="https://doi.org/10.1016/S2213-2600(18)30329-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30191832/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Respir%20Med&amp;title=Time%20to%20act%20on%20injectable-free%20regimens%20for%20children%20with%20multidrug-resistant%20tuberculosis&amp;volume=6&amp;publication_year=2018&amp;pages=662-4&amp;pmid=30191832&amp;doi=10.1016/S2213-2600(18)30329-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R35">
<span class="label">35.</span><cite>
Satyaraddi A, Velpandian T, Sharma SK, et al. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis
2014;18:188–95. 10.5588/ijtld.13.0128
</cite> [<a href="https://doi.org/10.5588/ijtld.13.0128" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24429311/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Tuberc%20Lung%20Dis&amp;title=Correlation%20of%20plasma%20anti-tuberculosis%20drug%20levels%20with%20subsequent%20development%20of%20hepatotoxicity&amp;volume=18&amp;publication_year=2014&amp;pages=188-95&amp;pmid=24429311&amp;doi=10.5588/ijtld.13.0128&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R36">
<span class="label">36.</span><cite>
Zheng X, Bao Z, Forsman LD, et al. Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response. Clin Infect Dis
2020:ciaa1569. 10.1093/cid/ciaa1569
</cite> [<a href="https://doi.org/10.1093/cid/ciaa1569" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33070176/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Drug%20exposure%20and%20minimum%20inhibitory%20concentration%20predict%20pulmonary%20tuberculosis%20treatment%20response&amp;publication_year=2020&amp;pages=ciaa1569&amp;pmid=33070176&amp;doi=10.1093/cid/ciaa1569&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R37">
<span class="label">37.</span><cite>
Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis
2017;17:39–49. 10.1016/S1473-3099(16)30274-2
</cite> [<a href="https://doi.org/10.1016/S1473-3099(16)30274-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5159618/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28100438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Infect%20Dis&amp;title=High-dose%20rifampicin,%20moxifloxacin,%20and%20SQ109%20for%20treating%20tuberculosis:%20a%20multi-arm,%20multi-stage%20randomised%20controlled%20trial&amp;volume=17&amp;publication_year=2017&amp;pages=39-49&amp;pmid=28100438&amp;doi=10.1016/S1473-3099(16)30274-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R38">
<span class="label">38.</span><cite>
Gafar F, Van't Boveneind-Vrubleuskaya N, Akkerman OW, et al. Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands. Eur Respir J
2019;54:1901402. 10.1183/13993003.01402-2019
</cite> [<a href="https://doi.org/10.1183/13993003.01402-2019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31515410/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Respir%20J&amp;title=Nationwide%20analysis%20of%20treatment%20outcomes%20in%20children%20and%20adolescents%20routinely%20treated%20for%20tuberculosis%20in%20the%20Netherlands&amp;volume=54&amp;publication_year=2019&amp;pages=1901402&amp;pmid=31515410&amp;doi=10.1183/13993003.01402-2019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R39">
<span class="label">39.</span><cite>
Donald PR, Schoeman JF, O'Kennedy A. Hepatic toxicity during chemotherapy for severe tuberculosis meningitis. Am J Dis Child
1987;141:741–3. 10.1001/archpedi.1987.04460070043019
</cite> [<a href="https://doi.org/10.1001/archpedi.1987.04460070043019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2884866/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Dis%20Child&amp;title=Hepatic%20toxicity%20during%20chemotherapy%20for%20severe%20tuberculosis%20meningitis&amp;volume=141&amp;publication_year=1987&amp;pages=741-3&amp;pmid=2884866&amp;doi=10.1001/archpedi.1987.04460070043019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R40">
<span class="label">40.</span><cite>
Ghimire S, Bolhuis MS, Sturkenboom MGG, et al. Incorporating therapeutic drug monitoring into the world Health organization hierarchy of tuberculosis diagnostics. Eur Respir J
2016;47:1867–9. 10.1183/13993003.00040-2016
</cite> [<a href="https://doi.org/10.1183/13993003.00040-2016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26989104/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Respir%20J&amp;title=Incorporating%20therapeutic%20drug%20monitoring%20into%20the%20world%20Health%20organization%20hierarchy%20of%20tuberculosis%20diagnostics&amp;volume=47&amp;publication_year=2016&amp;pages=1867-9&amp;pmid=26989104&amp;doi=10.1183/13993003.00040-2016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R41">
<span class="label">41.</span><cite>
Marais BJ, Heemskerk AD, Marais SS, et al. Standardized methods for enhanced quality and comparability of tuberculous meningitis studies. Clin Infect Dis
2017;64:501–9. 10.1093/cid/ciw757
</cite> [<a href="https://doi.org/10.1093/cid/ciw757" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5399942/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28172588/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Standardized%20methods%20for%20enhanced%20quality%20and%20comparability%20of%20tuberculous%20meningitis%20studies&amp;volume=64&amp;publication_year=2017&amp;pages=501-9&amp;pmid=28172588&amp;doi=10.1093/cid/ciw757&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R42">
<span class="label">42.</span><cite>
Rachow A, Clowes P, Saathoff E, et al. Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clin Infect Dis
2012;54:1388–96. 10.1093/cid/cis190
</cite> [<a href="https://doi.org/10.1093/cid/cis190" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22474220/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Increased%20and%20expedited%20case%20detection%20by%20Xpert%20MTB/RIF%20assay%20in%20childhood%20tuberculosis:%20a%20prospective%20cohort%20study&amp;volume=54&amp;publication_year=2012&amp;pages=1388-96&amp;pmid=22474220&amp;doi=10.1093/cid/cis190&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R43">
<span class="label">43.</span><cite>
Alffenaar J-WC, Gumbo T, Dooley KE, et al. Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis. Clin Infect Dis
2020;70:1774–80. 10.1093/cid/ciz942
</cite> [<a href="https://doi.org/10.1093/cid/ciz942" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7146003/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31560376/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Integrating%20pharmacokinetics%20and%20pharmacodynamics%20in%20operational%20research%20to%20end%20tuberculosis&amp;volume=70&amp;publication_year=2020&amp;pages=1774-80&amp;pmid=31560376&amp;doi=10.1093/cid/ciz942&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R44">
<span class="label">44.</span><cite>
Thwaites GE, Tran TH. Tuberculous meningitis: many questions, too few answers. Lancet Neurol
2005;4:160–70. 10.1016/S1474-4422(05)70019-3
</cite> [<a href="https://doi.org/10.1016/S1474-4422(05)70019-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15721826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Neurol&amp;title=Tuberculous%20meningitis:%20many%20questions,%20too%20few%20answers&amp;volume=4&amp;publication_year=2005&amp;pages=160-70&amp;pmid=15721826&amp;doi=10.1016/S1474-4422(05)70019-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>Supplementary data</span></div>
<p>
<a href="/articles/instance/8685623/bin/archdischild-2020-321426supp001.pdf" class="usa-link">archdischild-2020-321426supp001.pdf</a><sup> (518.1KB, pdf) </sup>
</p></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Archives of Disease in Childhood are provided here courtesy of <strong>BMJ Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1136/archdischild-2020-321426"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/archdischild-2020-321426.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.0 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/8685623/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/8685623/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC8685623%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC8685623/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC8685623/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC8685623/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/34183327/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC8685623/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/34183327/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC8685623/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/8685623/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="OB4bUjKXiEni8ellffblsuF12QTrmgjD6vb0iozLExKngplB9DxNNfVnJuBCrWnp">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
